linjc16/ctgov huggingface dataset:
Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day

Study Overview
=================
Brief Summary
-----------------
To salvage the luteal phase and improve pregnancy rate in antagonist IVF/ICSI cycles triggered with GnRH agonist. Two strategies are compared supplementing the luteal phase with three small doses (500 IU) of HCG and giving a booster dose of HCG (1500 IU) on the day of ovum pickup.

Official Title
-----------------
Supplementing the Luteal Phase With Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Procedure: IVF/ICSI
* Drug: Human Chorionic Gonadotropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High responder females undergoing antagonist protocol IVF/ICSI cycle More than 14 MII oocytes Estradiol more than 3500 pg/ml on day of trigger Exclusion Criteria: Any other protocol Normal or poor responders

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 37 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Small doses of HCG<br>Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders | Procedure: IVF/ICSI<br> <br> Drug: Human Chorionic Gonadotropin<br>* Given in different doses and timing to support the luteal phase<br>|
| Active Comparator: Booster HCG dose<br>Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup | Procedure: IVF/ICSI<br> <br> Drug: Human Chorionic Gonadotropin<br>* Given in different doses and timing to support the luteal phase<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | The number of cycles with a positive pregnancy test and evidence of a gestational sac with fetal pulsations after 5weeks from pregnancy test | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OHSS rate | The number of cycles with evidence of OHSS | 1 year |
Catechol Thioethers in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The goal of the clinical trial aim in this project is to test whether catechol thioethers can be used as biomarkers of dopaminergic neurodegeneration.

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
First diagnosis of Parkinson's disease.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
catechol thioethers, Parkinson's disease, neurodegenerative disease
Effects of Fresh Mango Pulp Consumption on Satiety and Cardiometabolic Health

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults.

Official Title
-----------------
Effects of Fresh Mango Pulp Consumption on Satiety and Cardiometabolic Health

Conditions
-----------------
Satiety

Intervention / Treatment
-----------------
* Other: Low fat cookie
* Other: Mango fruit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-55 years old BMI 27-40 Exclusion Criteria: Smoker Pregnant woman Required dietary supplement use Required medication of metabolic disorders Allergy to mango or gluten

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Low fat cookies<br>Subjects consume 100 kcal of low fat cookies daily for 12 weeks. | Other: Low fat cookie<br>* to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults<br>|
| Experimental: Mango fruit<br>Subjects consume 100 kcal of mango fruit daily for 12 weeks. | Other: Mango fruit<br>* to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of satiety | Change of hunger feeling (appetite) will be examined using visual analog scale (0-10): 0 least and 10 greatest | 0, 20, 40, 60, 90 and 120 minutes post snack consumption | 
| Change of glucose level | Change of blood glucose response will be determined to examine effects of mango consumption vs low fat cookie consumption | 0, 30, 60, 90 and 120 minutes post snack consumption; baseline and week 12 | 
| Change of insulin level | Change of blood insulin level will be determined to examine effects of mango consumption vs low fat cookie consumption | 0 and 60 minutes post snack consumption, baseline and week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of microbiome | Change of microbiome diversity will be determined to examine effects of mango consumption vs low fat cookie consumption | Baseline, week 4 and week12 |
Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS

Study Overview
=================
Brief Summary
-----------------
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system responsible for physical disability but can also cause cognitive disturbances annoying social and professional life of patients with the disease. Various studies have shown that there was a breach of episodic memory, working memory, attention and executive functions regardless of the form of disease, disability or duration of disease progression. The main objective of this study is to investigate the influence of emotional components and executive processes on the components retrograde and anterograde episodic memory (thanks to an original paradigm based on the emotional valence of the memory) in MS patients

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Behavioral: Neuropsychological tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women 30-60 years of age Definite MS (McDonald criteria revised in 2005) EDSS <6 Sick Shapes: Relapsing multiple sclerosis, Primary progressive multiple sclerosis All durations evolution French Mother tongue Signature of informed consent Exclusion Criteria: Other neurological conditions, previous psychiatric or developmental diagnosis of MS Head injury sequelae Chronic alcohol or drugs Taking EDSS greater than or equal to 6 Secondary Progressive Form Push and / or treatment with corticosteroids within one month Treatments Amantadine, Modafinil introduced for less than 3 months Patient Trust Cognitive Assessment of less than one year (including in particular all or part of the balance sheet proposed in this project) Any visual motor deficit or incompatible with the award of cognitive tests For women, pregnancy, breastfeeding and / or lack of contraception (a pregnancy test will be done before the PET scan) Patient with indications against MRI

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Neuropsychological tests<br> | Behavioral: Neuropsychological tests<br>* Neuropsychological tests<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anterograde episodic memory: 3 scores of emotional ESR | 3 scores of emotional ESR | baseline | 
| retrograde episodic memory: 9 scores TEMP emotional | 9 scores TEMP emotional | baseline |
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Study Overview
=================
Brief Summary
-----------------
This is a randomized, placebo-controlled, double-blind, multiple cohort, fixed-dose multiple crossover, dose-finding study of oral BTD-001 in adult patients with IH or Narcolepsy without cataplexy (Type 2).

Official Title
-----------------
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Conditions
-----------------
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy

Intervention / Treatment
-----------------
* Drug: BTD-001
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meets ICSD-3 criteria for IH or Narcolepsy Type 2 and not undergoing pharmacologic treatment for the condition Usual nightly total sleep at least 6 hours as single major rest period without naps Epworth Sleepiness Scale of 10 or greater Males or females age 18 to 65 years Exclusion Criteria: Any disorder causing hypersomnia other than IH or Narcolepsy Type 2 Usual bedtime later than midnight Seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years Beck Depression Inventory score greater than 19 Beck Anxiety Inventory score greater than 15 Significant history of or current suicidal ideation or behavior BMI less than 18 kg/m2 or greater than 39 kg/m2 Positive toxicology screen or breathalyzer test Clinically significant abnormal findings on safety assessments Any significant medical or psychiatric disease or any condition that would put the patient at risk by participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BTD-001<br> | Drug: BTD-001<br> <br> |
| Experimental: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy Epworth Sleepiness Scale | Epworth Sleepiness Scale | After 14 days per treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy Maintenance of Wakefulness Test | Maintenance of Wakefulness Test | After 14 days per treatment |
Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support

Study Overview
=================
Brief Summary
-----------------
Neurally adjusted ventilatory assist (NAVA) is a mode of mechanical ventilation that uses the diaphragm's normal electrical activity to deliver a mechanically supported breath. The amount of support provided is determined in part by the NAVA level, where a higher NAVA level will provide higher level of support and unload more of the work of the diaphragm. The purpose of this study is to compare the optimal NAVA level in neonates while on mechanical ventilation while intubated and after being extubated.

Detailed Description
-----------------
Baseline measurements will be taken. The NAVA titration study will then be done. The NAVA level will be set at a starting value of 0.1 cm H2O/mcV and systematically increased by 0.5 cm H2O/mcV every three minutes to a maximum of 3 cmH2O/mcV. Once the NAVA titration study has been completed, the patient will be extubated. There will be a stabilization period following extubation (15-30 minutes), and then the NAVA titration study will be repeated.

Official Title
-----------------
Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support

Conditions
-----------------
Other Specified Respiratory Problems in Fetus or Neonate

Intervention / Treatment
-----------------
* Procedure: NAVA level
* Other: NAVA level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates on NAVA ventilation Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 23 Weeks
Maximum Age: 40 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intubated<br>NAVA level from 0.1 to 3 | Procedure: NAVA level<br>* Peak inspiratory pressure will be measured at each NAVA level<br>Other: NAVA level<br>* Increase NAVA level every 3 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in breakpoint in intubated and extubated patients | NAVA titration study will be done pre and post extubation to determine and then compare the breakpoint. | 20 minute study pre and post extubation |
Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Autologous Dermal Fibroblasts

Study Overview
=================
Brief Summary
-----------------
Treatment of patients with non-healing wounds and trophic ulcers using local LED phototherapy with local transplantation of autologous dermal fibroblasts

Detailed Description
-----------------
During the implementation of the project, it was planned to develop a method for the treatment of trophic ulcers using injection of autologous dermal fibroblasts in the wound. The positive outlook for the effectiveness of photodiode therapy with dermal fibroblasts is due to the following: the ability of fibroblasts to stimulate tissue regeneration positive results of preclinical studies of the method of treatment of long-term non-healing wounds in animals (rats). Twelve patients were included in the study. Dermal fibroblasts were isolated from the skin patients, cultured and then transplanted back to the wound. The therapeutic dose of cells was 50k per cm2 of the wound area. Follow up patients monitoring was performed at 1, 2 and more months after injection.

Official Title
-----------------
Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Local LED Phototherapy and Autologous Dermal Fibroblasts

Conditions
-----------------
Trophic Ulcer, Non-healing Wound, Non-Healing Ulcer of Skin

Intervention / Treatment
-----------------
* Biological: Dermal fibroblasts
* Device: LED phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Trophic Ulcers Chronic non-healing wounds Exclusion Criteria: acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis mental disorders pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients treated with dermal fibroblasts<br>Cultured dermal fibroblasts and LED phototherepy | Biological: Dermal fibroblasts<br>* Cultured autologous dermal fibroblasts. For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.<br>Device: LED phototherapy<br>* LED phototherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with tropic ulcers cured | Number of patients cured | 1 month | 
| Number of patients with treatment-related adverse events | Fibroblasts injection related adverse events assessed by blood count and function tests | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Trophic Ulcer, Non-healing Wound, Dermal fibroblasts
Validation of the Korean Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to translate and validate the CAM-ICU for use in the Korean ICU setting.

Official Title
-----------------
Translation and Validation of the Korean Version of Confusion Assessment Method for the Intensive Care Unit

Conditions
-----------------
Critical Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years admitted to medical ICU at Seoul National University Hospital longer than 24 hours Exclusion Criteria: comatose or moribund state throughout the study period preexisting neurologic problem

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| medical ICU<br>admitted to medical ICU at Seoul National University Hospital longer than 24 hours | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interrater reliability of Korean CAM-ICU |  | after completion of study | 
| Sensitivity of Korean CAM-ICU for diagnosing ICU delirium |  | after completion of study | 
| Specificity of Korean CAM-ICU for diagnosing ICU delirium |  | after completion of study |
Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use

Study Overview
=================
Brief Summary
-----------------
The overarching goal of this online study is to compare the efficacy of six (weekly) sessions of Domain-Specific Episodic Future Thinking (DS-EFT) relative an active control condition on improving the ability to value future rewards and reducing cannabis use (grams and days of use), tobacco use, and alcohol use among.

Official Title
-----------------
Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use

Conditions
-----------------
Marijuana Use, Marijuana Dependence, Tobacco Use, Alcohol Use, Unspecified

Intervention / Treatment
-----------------
* Behavioral: Domain-Specific Episodic Future Thinking


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 or older reside in the U.S. report wanting to reduce cannabis use (4 or higher on scale of 1-10 with higher scores indicating greater desire to reduce use) report using cannabis at least 10 days in the last month report using cannabis at least 100 days in their lifetime Data quality checks passed Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Domain-Specific Episodic Future Thinking<br> | Behavioral: Domain-Specific Episodic Future Thinking<br>* Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.<br>|
| Active Comparator: Episodic Recent Thinking Control Condition<br> | Behavioral: Domain-Specific Episodic Future Thinking<br>* Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cannabis use grams |  | 1-week follow-up | 
| Number of cannabis use days |  | 1-week follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of tobacco use days |  | 1-week follow-up | 
| Number of alcohol use days |  | 1-week follow-up | 
| Number of tobacco use times |  | 1-week follow-up | 
| Number of alcoholic drinks |  | 1-week follow-up | 
| Rate of delay discounting | 5-trial adjusting delay discounting task | 1-week follow-up |